Published in Curr Opin HIV AIDS on July 01, 2012
Pharmacokinetics and 48-week safety and antiviral activity of fosamprenavir-containing regimens in HIV-infected 2- to 18-year-old children. Pediatr Infect Dis J (2014) 0.82
Effects of postnatal interventions for the reduction of vertical HIV transmission on infant growth and non-HIV infections: a systematic review. J Int AIDS Soc (2013) 0.77
Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis (2011) 3.59
Methods to recruit hard-to-reach groups: comparing two chain referral sampling methods of recruiting injecting drug users across nine studies in Russia and Estonia. J Urban Health (2006) 2.52
Explosive spread and high prevalence of HIV infection among injecting drug users in Togliatti City, Russia. AIDS (2002) 2.40
Response to combination antiretroviral therapy: variation by age. AIDS (2008) 2.28
Risk of triple-class virological failure in children with HIV: a retrospective cohort study. Lancet (2011) 1.90
Differences in factors associated with initial growth, CD4, and viral load responses to ART in HIV-infected children in Kampala, Uganda, and the United Kingdom/Ireland. J Acquir Immune Defic Syndr (2008) 1.75
Survey of children accessing HIV services in a high prevalence setting: time for adolescents to count? Bull World Health Organ (2009) 1.59
Effects of sex work on the prevalence of syphilis among injection drug users in 3 Russian cities. Am J Public Health (2006) 1.54
Effect of early antiretroviral therapy on the risk of AIDS/death in HIV-infected infants. AIDS (2009) 1.49
Outcomes after viral load rebound on fi rst-line antiretroviraltreatment in children with HIV in the UK and Ireland:an observational cohort study. Lancet HIV (2015) 1.42
Injecting equipment sharing among injecting drug users in Togliatti City, Russian Federation: maximizing the protective effects of syringe distribution. J Acquir Immune Defic Syndr (2004) 1.37
Hepatitis C and its risk management among drug injectors in London: renewing harm reduction in the context of uncertainty. Addiction (2004) 1.31
High HIV prevalence among injecting drug users in Estonia: implications for understanding the risk environment. AIDS (2006) 1.30
Drug-related mortality and fatal overdose risk: pilot cohort study of heroin users recruited from specialist drug treatment sites in London. J Urban Health (2003) 1.29
Young people in the United Kingdom and Ireland with perinatally acquired HIV: the pediatric legacy for adult services. AIDS Patient Care STDS (2009) 1.23
Predicting patterns of long-term CD4 reconstitution in HIV-infected children starting antiretroviral therapy in sub-Saharan Africa: a cohort-based modelling study. PLoS Med (2013) 1.19
Hepatitis C virus infection, HIV co-infection, and associated risk among injecting drug users in Togliatti, Russia. Int J STD AIDS (2005) 1.18
Prevalence of personality disorder in alcohol and drug services and associated comorbidity. Addiction (2004) 1.15
Effectiveness of antiretroviral therapy in HIV-infected children under 2 years of age. Cochrane Database Syst Rev (2012) 1.13
Triple-class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 years. Arch Intern Med (2010) 1.12
Young HIV-infected children and their adult caregivers prefer tablets to syrup antiretroviral medications in Africa. PLoS One (2012) 1.05
Increasing the uptake of hepatitis C virus testing among injecting drug users in specialist drug treatment and prison settings by using dried blood spots for diagnostic testing: a cluster randomized controlled trial. J Viral Hepat (2007) 1.05
Low incidence of abacavir hypersensitivity reaction among African children initiating antiretroviral therapy. Pediatr Infect Dis J (2011) 1.05
Development of antiretroviral resistance in children with HIV in low- and middle-income countries. J Infect Dis (2013) 0.99
Over a decade of syringe exchange: results from 1997 UK survey. Addiction (2002) 0.98
Barriers to Initiation of Pediatric HIV Treatment in Uganda: A Mixed-Method Study. AIDS Res Treat (2012) 0.97
The clinical pattern, prevalence, and factors associated with immune reconstitution inflammatory syndrome in Ugandan children. AIDS (2010) 0.96
Incidence and risk factors for first line anti retroviral treatment failure among Ugandan children attending an urban HIV clinic. AIDS Res Ther (2013) 0.95
HIV prevalence among injecting drug users in England and Wales 1990 to 2003: evidence for increased transmission in recent years. AIDS (2005) 0.94
Maintaining the nelfinavir trough concentration above 0.8 mg/L improves virologic response in HIV-1-infected children. J Pediatr (2004) 0.93
Tenofovir use in human immunodeficiency virus-1-infected children in the United kingdom and Ireland. Pediatr Infect Dis J (2009) 0.93
Use of combination neonatal prophylaxis for the prevention of mother-to-child transmission of HIV infection in European high-risk infants. AIDS (2013) 0.90
Outcomes after reinitiating antiretroviral therapy in children randomized to planned treatment interruptions. AIDS (2013) 0.88
Adherence to antiretroviral therapy in HIV-positive adolescents in Uganda assessed by multiple methods: a prospective cohort study. Paediatr Drugs (2012) 0.88
Short- and long-term immunological and virological outcome in HIV-infected infants according to the age at antiretroviral treatment initiation. Clin Infect Dis (2011) 0.87
Long-term virological outcome in children on antiretroviral therapy in the UK and Ireland. AIDS (2014) 0.87
Post-licensing safety of fosamprenavir in HIV-infected children in Europe. Pharmacoepidemiol Drug Saf (2014) 0.86
Translating evidence into policy in low-income countries: lessons from co-trimoxazole preventive therapy. Bull World Health Organ (2011) 0.84
Transmission of hepatitis C--are noninjecting cocaine users at risk? Subst Use Misuse (2002) 0.84
Prevalence of lipodystrophy and metabolic abnormalities in HIV-infected African children after 3 years on first-line antiretroviral therapy. Pediatr Infect Dis J (2015) 0.83
Psychosocial challenges and strategies for coping with HIV among adolescents in Uganda: a qualitative study. AIDS Patient Care STDS (2015) 0.82
The prevalence of darunavir-associated mutations in HIV-1-infected children in the UK. Antivir Ther (2011) 0.82
Pubertal development in HIV-infected African children on first-line antiretroviral therapy. AIDS (2015) 0.82
Disclosure of HIV Status to Perinatally Infected Adolescents in Urban Uganda: A Qualitative Study on Timing, Process, and Outcomes. J Assoc Nurses AIDS Care (2015) 0.81
HIV-associated anemia after 96 weeks on therapy: determinants across age ranges in Uganda and Zimbabwe. AIDS Res Hum Retroviruses (2014) 0.81
Short communication: high rates of thymidine analogue mutations and dual-class resistance among HIV-infected Ugandan children failing first-line antiretroviral therapy. AIDS Res Hum Retroviruses (2013) 0.80
A Case of Cryptococcal Lymphadenitis in an HIV-Infected Child. AIDS Res Hum Retroviruses (2010) 0.80
Opportunities for improving the efficiency of paediatric HIV treatment programmes. AIDS (2015) 0.79
Development of a psychosocial distress measure for Ugandan adolescents living with HIV. AIDS Behav (2015) 0.79
Immediate antiretroviral therapy in young HIV-infected children: benefits and risks. Curr Opin HIV AIDS (2014) 0.79
Single Genome Analysis for the Detection of Linked Multiclass Drug Resistance Mutations in HIV-1-Infected Children After Failure of Protease Inhibitor-Based First-Line Therapy. J Acquir Immune Defic Syndr (2015) 0.78
Children with HIV are not small adults: what is different in pharmacology? Curr Opin HIV AIDS (2007) 0.77
Lopinavir dosing in HIV-infected children in the United Kingdom and Ireland. Pediatr Infect Dis J (2013) 0.77
HIV-1 Drug Resistance and Second-Line Treatment in Children Randomized to Switch at Low Versus Higher RNA Thresholds. J Acquir Immune Defic Syndr (2015) 0.75
Cardiac Dysfunction Among Ugandan HIV-infected Children on Antiretroviral Therapy. Pediatr Infect Dis J (2016) 0.75
Brief Report: Prevalence of Latent Rheumatic Heart Disease Among HIV-Infected Children in Kampala, Uganda. J Acquir Immune Defic Syndr (2016) 0.75
Does the CHER trial open up new therapeutic perspectives? Lancet (2013) 0.75
Survival of HIV-1 vertically infected children. Curr Opin HIV AIDS (2016) 0.75
Insulin Resistance and Markers of Inflammation in HIV-Infected Ugandan Children in the CHAPAS 3 Trial. Pediatr Infect Dis J (2017) 0.75
Incidence of pneumococcal and varicella disease in HIV-infected children and adolescents in the United Kingdom and Ireland, 1996-2011. Pediatr Infect Dis J (2015) 0.75
Virologic Response to First-line Efavirenz- or Nevirapine-based Antiretroviral Therapy in HIV-infected African Children. Pediatr Infect Dis J (2017) 0.75
Who Gets Severe Gynecomastia Among HIV-Infected Children In The UK And Ireland? Pediatr Infect Dis J (2016) 0.75
Unmet needs persist in pediatric HIV programs: lessons from selected case studies in Uganda. AIDS (2017) 0.75
Virologic Response to First-Line Efavirenz- or Nevirapine-Based Anti-Retroviral Therapy in HIV-Infected African Children. Pediatr Infect Dis J (2016) 0.75